Alembic Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE901L01018
  • NSEID: APLLTD
  • BSEID: 533573
INR
835.70
-14.65 (-1.72%)
BSENSE

Sep 22, 03:32 PM

BSE+NSE Vol: 99.28 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Marksans Pharma
Corona Remedies
Alivus Life
Sudeep Pharma
Alembic Pharma
Concord Biotech
OneSource Speci.
Cohance Life
Astrazeneca Phar
Jubilant Pharmo
Natco Pharma

Why is Alembic Pharmaceuticals Ltd. ?

1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.28 times
2
Poor long term growth as Operating profit has grown by an annual rate -6.71% of over the last 5 years
3
Flat results in Jun 26
  • INTEREST(Q) Highest at Rs 27.61 cr
4
With ROCE of 11.6, it has a Attractive valuation with a 2.6 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -11.04%, its profits have risen by 27.1% ; the PEG ratio of the company is 0.8
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Alembic Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Alembic Pharma for you?

Medium Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Alembic Pharma
-12.03%
-0.41
26.99%
Sensex
-9.29%
-0.67
13.52%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
7.68%
EBIT Growth (5y)
-6.71%
EBIT to Interest (avg)
11.07
Debt to EBITDA (avg)
1.02
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.03
Tax Ratio
4.98%
Dividend Payout Ratio
37.06%
Pledged Shares
0
Institutional Holding
20.12%
ROCE (avg)
11.33%
ROE (avg)
10.96%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
22
Industry P/E
38
Price to Book Value
2.94
EV to EBIT
21.67
EV to EBITDA
15.32
EV to Capital Employed
2.59
EV to Sales
2.30
PEG Ratio
0.82
Dividend Yield
1.41%
ROCE (Latest)
11.59%
ROE (Latest)
12.93%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
PAT(9M)

At Rs 568.00 cr has Grown at 26.31%

NET SALES(Q)

Highest at Rs 2,149.77 cr

PBDIT(Q)

Highest at Rs 331.86 cr.

-3What is not working for the Company
INTEREST(Q)

Highest at Rs 27.61 cr

Loading Valuation Snapshot...

Here's what is working for Alembic Pharma

Profit After Tax (PAT) - Latest six months
At Rs 400.53 cr has Grown at 28.68%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 2,149.77 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 2,149.77 cr has Grown at 25.66%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 331.86 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Here's what is not working for Alembic Pharma

Interest - Quarterly
Highest at Rs 27.61 cr
in the last five quarters and Increased by 22.38 % (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)